Document is current
Any future updates will be listed below
-
Authors
Roldan Urgoiti, Gloria https://orcid.org/0000-0002-9762-5415
de Robles, Paula
Tsang, Roger Y.
Willson, Morgan
Ghosh, Sunita
Faruqi, Muhammad
Lim, Gerald
Loewen, Shaun
Nordal, Robert
Cairncross, Gregory
Leckie, Catriona
Poon, Candice C.
Yong, V. Wee
-
Funding
Funding for this research was provided by:
Alberta Cancer Foundation, Canada
Canadian Institutes of Health Research
Alberta Cancer Foundation
- License Information
-
More Information
Article History
Received: 17 October 2025
Accepted: 24 November 2025
First Online: 28 November 2025
Declarations
:
: Good Clinical Practice (ICH-GCP) Guidelines under a Clinical Trial Application (CTA) for a natural health product (NHP) with Health Canada. It obtained local ethics board approval (HREBA cc 20–0402) before starting. All patients signed informed consent. Data Safety Monitoring Committee (DSMC) meetings were planned per protocol at the completion of phase I, after the interim analysis and at the end of phase II. The trial is registered in clinicaltrials.gov as NCT04677049.
: Written informed consent was obtained from all individual participants included in the study.
: All authors have consented to publish this paper. This material was accepted as poster in the Canadian Cancer Research Conference, Calgary AB, Nov 2–4, 2025.
: The authors declare no competing interests.
